Oxford, UK - March 17, 2026. Enara Bio, a pioneer in Dark Antigen® discovery and bispecific T cell engager innovation, today ...
Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.
We owe a lot to tissue resident memory T cells (T RM). These specialized immune cells are among the body's first responders to disease. Rather than coursing through the bloodstream-as many T cells ...
Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells ...
A paper published in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel synthetic ligand that activates the Notch signaling pathway, a key driver in ...
The Notch signaling pathway plays a pivotal role in determining cell fate, especially in the development and function of T cells. But mimicking this highly mechanical, contact-dependent pathway in the ...
The US Food and Drug Administration’s (FDA) guidance documents offer sponsors greater clarity on trial designs and control strategies that could potentially accelerate the development of in vivo CAR-T ...
Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results